Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
Karen Barnard1,2, Mary Elizabeth Cox1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, U...
Main Authors: | Green J, Karen K, Cox ME |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-10-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/clinical-utility-of-fixed-combinations-of-sitagliptinndashmetformin-in-peer-reviewed-article-DMSO |
Similar Items
-
Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
by: Naoko Tajima, et al.
Published: (2020-05-01) -
The effect of sitagliptin on hepatic ischemic reperfusion injury in rats
by: Song-Chol Mun, et al.
Published: (2020-01-01) -
Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study
by: Shih-Yi Lin, et al.
Published: (2018-06-01) -
Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy
by: Lorenzoni V, et al.
Published: (2017-11-01) -
Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures
by: Dong-Hou Kim, et al.
Published: (2012-04-01)